Zevra Therapeutics Inc.

7.33
-0.16 (-2.14%)
At close: Apr 01, 2025, 3:59 PM
7.38
0.68%
After-hours: Apr 01, 2025, 07:55 PM EDT

Company Description

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate.

It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial.

In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics Inc.
Zevra Therapeutics Inc. logo
Country United States
IPO Date Apr 16, 2015
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Neil F. McFarlane

Contact Details

Address:
1180 Celebration Boulevard
Celebration, Florida
United States
Website https://zevra.com

Stock Details

Ticker Symbol ZVRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001434647
CUSIP Number n/a
ISIN Number US4884452065
Employer ID 20-5894398
SIC Code 2834

Key Executives

Name Position
Neil F. McFarlane President, Chief Executive Officer & Director
Alison Peters Chief People Officer
R. LaDuane Clifton CPA Chief Financial Officer & Treasurer
Rahsaan W. Thompson J.D. Chief Legal Officer, Secretary & Compliance Officer
Dr. Adrian Quartel FFPM, M.D. Chief Medical Officer
Dr. Christopher M. Lauderback Ph.D. Senior Vice President of Manufacturing
Dr. Daniel Gallo Ph.D. Senior Vice President of Medical Affairs & Advocacy
Dr. Rene A. Braeckman Ph.D. Senior Vice President of Clinical Development
Joshua M. Schafer M.B.A. Chief Commercial Officer & Executive Vice President of Business Development
Nichol L. Ochsner Vice President of Investor Relations & Corporate Communications

Latest SEC Filings

Date Type Title
Mar 31, 2025 4 Filing
Mar 31, 2025 DEFA14A Filing
Mar 31, 2025 DEFA14A Filing
Mar 31, 2025 PREC14A Filing
Mar 27, 2025 4 Filing
Mar 27, 2025 3 Filing
Mar 21, 2025 4 Filing
Mar 13, 2025 S-8 Filing
Mar 12, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report